Focus on radioiodine-131 biokinetics: the influence of methylprednisolone on intratherapeutic effective half-life of 131I during radioiodine therapy of Graves’ disease
- Aim: Radioiodine therapy (RIT) may trigger the development of Graves’ ophthalmopathy (GO) or exacerbate pre-existing subclinical GO. Therefore, glucocorticoid administration is recommended for patients with pre-existing GO. Aim of this study was to analyze the influence of glucocorticoid therapy with methylprednisolone on intratherapeutic effective half-life (EHL) of radioiodine-131 in patients with Graves’ disease (GD) as recent studies showed an effect for prednisolone. Methods: In a retrospective study, 264 patients with GD who underwent RIT without any additional antithyroid medication were evaluated. Intrathyroidal EHL was determined pre- and intratherapeutically. Patients with co-existing GO (n = 43) received methylprednisolone according to a fixed scheme starting 1 day prior to RIT, patients without GO (n = 221) did not receive any protective glucocorticoid medication. The ratios of EHL during RIT and during radioiodine uptake test (RIUT) were compared. Results: Patients receiving methylprednisolone showed a slight decrease of the mean EHL from 5.63 d (RIUT) to 5.39 d (RIT) (p > 0.05). A comparable result was obtained in patients without glucocorticoids (5.71 d (RIUT) to 5.47 d (RIT); p > 0.05). The ratios of the EHL between RIT and RIUT failed to show a significant difference between the two groups. EHL is therefore not significantly influenced by an additional protective treatment with methylprednisolone. Conclusions: In the present study a decreased intrathyroidal EHL under glucocorticoid medication with methylprednisolone could not be detected. Therefore, co-medication with methylprednisolone in patients with GO may be preferred to avoid an intratherapeutic decrease of EHL by accompanying protective glucocorticoides.
Author: | Christian HappelORCiDGND, Wolfgang Tilman Kranert, Daniel GrönerORCiDGND, Justus BaumgartenGND, Jörg HalstenbergGND, Benjamin Bockisch, Amir SabetORCiDGND, Frank GrünwaldGND |
---|---|
URN: | urn:nbn:de:hebis:30:3-747364 |
DOI: | https://doi.org/10.1007/s12020-020-02593-x |
ISSN: | 1559-0100 |
Parent Title (English): | Endocrine |
Publisher: | Springer |
Document Type: | Article |
Language: | English |
Date of Publication (online): | 2021/01/13 |
Date of first Publication: | 2021/01/13 |
Publishing Institution: | Universitätsbibliothek Johann Christian Senckenberg |
Release Date: | 2023/10/13 |
Tag: | Effective half-life; Graves’ disease; Radioiodine therapy; Radioiodine uptake test; Thyroid |
Volume: | 73 |
Issue: | 1 |
Page Number: | 6 |
First Page: | 125 |
Last Page: | 130 |
Note: | Open Access funding enabled and organized by Projekt DEAL. |
HeBIS-PPN: | 516360396 |
Institutes: | Medizin |
Dewey Decimal Classification: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
Sammlungen: | Universitätspublikationen |
Licence (German): | Creative Commons - CC BY - Namensnennung 4.0 International |